Campus Alert: Find the latest UMMS campus news and resources at umassmed.edu/coronavirus

Search Close Search

Print

Times quotes Julia Johnson on risk of new hot flash drugs

By Lisa M. Larson

UMass Medical School Communications

March 04, 2013

Julia Johnson, MD, chair and professor of obstetrics & gynecology and chair of the FDA’s advisory committee for reproductive health drugs, is quoted in a New York Times article today on why her panel voted to reject two new drugs for menopausal hot flashes.

The advisory committee for reproductive health drugs voted against Depomed’s extended-release gabapentin and a low-dose formulation of the antidepressant paroxetine developed by Noven Pharmaceuticals, saying the risks far outweighed minimal benefits.

“The risk of medications cannot be ignored for a treatment of marginal effectiveness,” Dr. Johnson said, according to the Times article.

Read the full story: F.D.A. Panel Advises Against Two Medicines to Treat Hot Flashes